Cleveland Diagnostics manufactures assays and provides CLIA lab services for early cancer detection. Our proprietary Solvent Interaction Analysis technology can improve specificity by investigating protein structure to provide insight into whether the biomarker originated from cancer cells or not. Our IsoPSA test is available to assess risk of high-grade prostate cancer. Tests for lung cancer, breast cancer, neurological disease and ID are under development. Learn more at www.ClevelandDx.com
Text
Cancel OK
